Fingerprint construction and detection method of Xinyi rhinitis preparation

Through ultra-high performance liquid chromatography and mass spectrometry combined determination, the fingerprint map of the maritime rhinitis preparation was established, which solved the problem of difficulty in comprehensive quality control in the existing technology, and achieved precise reflection and quality evaluation of the overall chemical composition of the maritime rhinitis preparation.

CN115128186BActive Publication Date: 2024-11-01GUANGZHOU BAIYUNSHAN ZHONGYI PHARMACEUTICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202210779082.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-07-04
Publication Date
2024-11-01
Estimated Expiration
2042-07-04

AI Technical Summary

Technical Problem

The prior art is difficult to conduct comprehensive and overall quality control and evaluation of marinated rhinitis preparations, mainly focusing on thin layer chromatography identification and high-performance liquid phase measurement of certain components, and lacking a comprehensive reflection of the overall chemical composition.

Method used

Ultra-high performance liquid chromatography technology was used, combined with gradient elution, multi-wavelength ultraviolet detection and mass spectrometry to establish the fingerprint of the magnolia rhinitis preparation. The 32 common peaks were determined by the reference of the citronellin peak, and the chromatographic fingerprint map was constructed. Achieve overall quality control and evaluation.

Benefits of technology

The accuracy and comprehensiveness of the quality control of the mammal rhinitis preparation is improved. The obtained fingerprint map can better reflect the material basis, realize the overall quality control and evaluation of the mammal rhinitis preparation, and has good precision and stability.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115128186B_ABST
    Figure CN115128186B_ABST
Patent Text Reader

Abstract

The invention provides a fingerprint construction method for a magnolia rhinitis preparation, comprising the following steps: mixing cimicifugin glycosides, cimicifugin, chlorogenic acid, magnolidin, DL-menthol, glycyrrhizic acid, glycyrrhetinic acid, ammonium glycyrrhizinate, liquiritin, isoliquiritigenin, liquiritigenin, licorice chalcone B, isoliquiritigenin, licorice chalcone, licorice chalcone A, glabridin, patchouli alcohol, geraniol, epigoitrin, psoralen, rutin, quercetin, isoquercetin, luteolin, acacia glycosides, luteolin, magnolin, imperatorin, isoimperatorin, and acacetin reference substances with methanol to prepare a mixed reference substance solution; taking the magnolia rhinitis preparation to prepare a test solution; respectively performing ultra-high performance liquid chromatography determination on the mixed reference substance solution and the test solution; wherein the conditions of the ultra-high performance liquid chromatography include: mobile phase A is formic acid aqueous solution, and mobile phase B is acetonitrile.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine detection, and in particular to a fingerprint construction method of a magnolia rhinitis preparation, a component-based identification construction method and a detection method. Background Art

[0002] With the development and widespread application of traditional Chinese medicine fingerprint technology, based on the fact that traditional Chinese medicine fingerprint can systematically and comprehensively reflect the common characteristic peaks contained in Chinese medicinal materials or Chinese patent medicines, traditional Chinese medicine fingerprint technology has become an important means of controlling Chinese medicinal materials and Chinese patent medicines, and has been widely used in the overall quality control of various Chinese medicinal materials and Chinese patent medicines.

[0003] The prescription of Xinyi rhinitis preparation is composed of Xanthium sibiricum, Xinyi, mint, Fangfeng, Dahurian angelica, chrysanthemum, perilla leaf, patchouli, Gebushicao, Isatis root, Houttuynia cordata, Trichosanthes and Licorice, and is included in the 2020 edition of the Chinese Pharmacopoeia. Long-term clinical application and clinical trials have proved that Xinyi rhinitis preparation has a definite clinical efficacy in the treatment of acute rhinitis, chronic rhinitis and allergic rhinitis. It has advantages over similar drugs in improving patients' rhinitis symptoms and signs and improving their quality of life.

[0004] Traditional technology discloses the thin layer identification and content determination methods of single medicinal materials. For magnolia rhinitis preparations, only the thin layer identification of 6 medicinal materials and the high-performance liquid phase content determination methods of two components are disclosed; some traditional technologies only determine the content of cimicifuga glycosides, liquiritin, 5-O-methylvisaminol glycosides and ammonium glycyrrhizinate in magnolia rhinitis preparations; in addition, there are traditional technologies that have established gas phase characteristic spectrum inspection methods for magnolia, patchouli, perilla leaves and mint, but this method mainly inspects the volatile components in the four medicinal materials of magnolia, patchouli, perilla leaves and mint in magnolia rhinitis preparations. It can be seen that the current quality research on magnolia rhinitis preparations mainly focuses on the thin layer chromatography identification of magnolia rhinitis preparations and the high-performance liquid phase content determination of components such as cimicifuga glycosides, 5-O-methylvisaminol glycosides, liquiritin, ammonium glycyrrhizinate, glycyrrhizic acid, etc. in magnolia rhinitis preparations, which makes it difficult to conduct comprehensive and overall quality control and evaluation of magnolia rhinitis preparations. Summary of the invention

[0005] Based on this, the present invention provides a fingerprint construction method for magnolia rhinitis preparations, which can comprehensively reflect the overall chemical composition of magnolia rhinitis preparations, improve the accuracy and comprehensiveness of magnolia rhinitis preparation quality control, and is more conducive to comprehensive and holistic quality control and evaluation of magnolia rhinitis preparations.

[0006] The present invention is achieved through the following technical solutions.

[0007] A method for constructing a fingerprint spectrum of a magnolia rhinitis preparation comprises the following steps:

[0008] Mix the reference substances of cimicifugin glycoside, cimicifugin, chlorogenic acid, magnolidin, DL-menthol, glycyrrhizic acid, glycyrrhetinic acid, ammonium glycyrrhizinate, liquiritin, isoliquiritigenin, liquiritigenin, licorice chalcone B, isoliquiritigenin, licorice chalcone A, glabridin, patchouli alcohol, geraniol, epigoitrin, psoralen, rutin, quercetin, isoquercetin, luteolin, acacia glycoside, luteolin, magnolin, imperatorin, isoimperatorin, and acacetin with methanol to prepare a mixed reference substance solution;

[0009] Take the Xinyi rhinitis preparation and prepare the test solution;

[0010] Performing ultra-high performance liquid chromatography on the mixed reference solution and the test solution respectively;

[0011] Wherein, the conditions of the ultra-high performance liquid chromatography include: mobile phase A is formic acid aqueous solution, and mobile phase B is acetonitrile.

[0012] In one embodiment, the conditions of the ultra-high performance liquid chromatography include: gradient elution; the gradient elution method is: 0min~10min, the volume percentage of mobile phase B is maintained at 3%; 10min~50min, the volume percentage of mobile phase B changes from 3% to 15%; 50min~60min, the volume percentage of mobile phase B changes from 15% to 25%; 60min~80min, the volume percentage of mobile phase B changes from 25% to 60%; 80min~90min, the volume percentage of mobile phase B changes from 60% to 100%.

[0013] In one embodiment, the ultra-high performance liquid chromatography conditions include electrospray detection or multi-wavelength ultraviolet detection.

[0014] In one embodiment, the wavelength of multi-wavelength ultraviolet detection is 254nm~281nm.

[0015] In one embodiment, the conditions of the ultra-high performance liquid chromatography include: a flow rate of 0.1 mL / min to 0.6 mL / min; a column temperature of 35° C. to 45° C.; and a chromatographic column of octadecylsilane bonded silica gel column.

[0016] In one embodiment, the dimensions of the octadecylsilane bonded silica gel column include: a particle size of 1.5 μm to 3.5 μm, a column length of 50 mm to 180 mm, and an inner diameter of 1.5 mm to 2.5 mm.

[0017] In one of the embodiments, the volume fraction of formic acid in the formic acid aqueous solution is 0.1% to 0.4%.

[0018] In one embodiment, preparing the mixed reference solution comprises the following steps:

[0019] The standard stock solution was prepared by mixing the reference substances of cimicifuga glycosides, cimicifuga, chlorogenic acid, magnolidin, DL-menthol, glycyrrhizic acid, glycyrrhetinic acid, ammonium glycyrrhizinate, liquiritin, isoliquiritigenin, liquiritigenin, licorice chalcone B, isoliquiritigenin, spiny licorice chalcone, licorice chalcone A, glabridin, patchouli alcohol, geraniol, epigoitrin, psoralen, rutin, quercetin, isoquercetin, luteolin, acacia glycosides, luteolin, magnolin, imperatorin, isoimperatorin and acacetin with methanol, and the solution was stored in a dark place and refrigerated. The standard stock solution was diluted before use.

[0020] In one embodiment, preparing the test solution comprises the following steps:

[0021] The magnolia nasitis preparation is mixed with methanol with a mass fraction of 10% to 100%, ultrasonically extracted, and then filtered. The filtrate is centrifuged and filtered again to obtain the filtrate.

[0022] In one embodiment, the conditions for ultrasonic extraction include: power of 120W to 145W, frequency of 35kHz to 45kHz, time of 10min to 90min, and temperature of 20°C to 35°C.

[0023] The present invention also provides a method for constructing a component-based identification of a Xinyi rhinitis preparation, comprising the following steps:

[0024] Take the Xinyi rhinitis preparation, mix it with 10% to 100% methanol by mass, extract it by ultrasonic, then filter it, centrifuge the filtrate, filter it again, take the filtrate, and prepare the test solution;

[0025] The test solution is subjected to ultra-high performance liquid chromatography-mass spectrometry;

[0026] The conditions used in the ultra-high performance liquid chromatography are consistent with the conditions used in the ultra-high performance liquid chromatography described above.

[0027] In one embodiment, the mass spectrometry conditions include: the ionization mode is electrospray ionization; the spray voltage is 3.5 kV to 5.0 kV; the ion transfer tube temperature is 320° C. to 400° C.; the maximum ion injection time of the first-stage full scan is 250 ms to 350 ms; the maximum ion injection time of the multi-stage scan is 100 ms to 200 ms;

[0028] The scanning mode is positive and negative ion scanning; the scanning range is 100m / z~1500m / z; the scanning resolution is 20000~40000; the corresponding strongest and second strongest ions in the full scan are subjected to dipole data-dependent scanning; the fragmentation mode is collision-induced fragmentation, and the collision energy is 30%~40%.

[0029] The present invention also provides a method for detecting a magnolia rhinitis preparation, comprising the following steps:

[0030] Take the Xinyi rhinitis preparation, mix it with 10% to 100% methanol by mass, extract it by ultrasonic, then filter it, centrifuge the filtrate, filter it again, take the filtrate, and prepare the test solution;

[0031] The solution to be tested is subjected to ultra-high performance liquid chromatography;

[0032] The conditions used in the ultra-high performance liquid chromatography are consistent with the conditions used in the ultra-high performance liquid chromatography described above.

[0033] Compared with the prior art, the fingerprint spectrum construction method of the magnolia rhinitis preparation of the present invention has the following beneficial effects:

[0034] The present invention uses ultra-high performance liquid chromatography technology, limits the mobile phase to acetonitrile and formic acid aqueous solution, establishes a chromatographic fingerprint of the Xinyi rhinitis preparation, determines 32 common peaks with the cimicifuga glycoside peak as the reference peak, and attributes the common peaks. The chromatographic fingerprint construction method established by the present invention has good precision, stability and repeatability, and the obtained fingerprint can more comprehensively reflect the material basis of Xinyi rhinitis pills, and realize the control and evaluation of the overall quality of the Xinyi rhinitis preparation. BRIEF DESCRIPTION OF THE DRAWINGS

[0035] Figure 1 UPLC spectra of 12 batches of Xinyi Biyan Pill samples provided by the present invention;

[0036] Figure 2 The standard fingerprint of Xinyi Biyan Pill provided by the present invention;

[0037] Figure 3 Chromatograms of samples of Xinyi Biyan Pills with different extraction solvents provided by the present invention;

[0038] Figure 4 Chromatograms of samples of Xinyi Biyan Pills at different extraction times provided by the present invention;

[0039] Figure 5 Chromatograms of Xinyi Biyan Pill sample detection using different detectors provided by the present invention;

[0040] Figure 6 Separation chromatograms of different mobile phase systems provided by the present invention;

[0041] Figure 7 Separation chromatograms of different mobile phase additives provided by the present invention;

[0042] Figure 8 Separation chromatograms at different chromatographic column temperatures provided by the present invention;

[0043] Fig. 9 A chromatogram of a gradient elution sample provided by the present invention;

[0044] Fig.10 A chromatogram of the test product provided by the present invention;

[0045] Fig.11 This is the mass spectrometry detection spectrum of the sample provided by the present invention. DETAILED DESCRIPTION

[0046] In order to facilitate the understanding of the present invention, the present invention will be described more fully below with reference to the relevant drawings. The preferred embodiments of the present invention are given in the drawings. However, the present invention can be implemented in many different forms and is not limited to the embodiments described herein. On the contrary, the purpose of providing these embodiments is to make the understanding of the disclosure of the present invention more thorough and comprehensive.

[0047] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.

[0048] The present invention provides a method for constructing a fingerprint spectrum of a magnolia rhinitis preparation, comprising the following steps:

[0049] Mix the reference substances of cimicifugin glycoside, cimicifugin, chlorogenic acid, magnolidin, DL-menthol, glycyrrhizic acid, glycyrrhetinic acid, ammonium glycyrrhizinate, liquiritin, isoliquiritigenin, liquiritigenin, licorice chalcone B, isoliquiritigenin, licorice chalcone A, glabridin, patchouli alcohol, geraniol, epigoitrin, psoralen, rutin, quercetin, isoquercetin, luteolin, acacia glycoside, luteolin, magnolin, imperatorin, isoimperatorin, and acacetin with methanol to prepare a mixed reference substance solution;

[0050] Take the Xinyi rhinitis preparation and prepare the test solution;

[0051] The mixed reference solution and the test solution were respectively subjected to ultra-high performance liquid chromatography determination;

[0052] The conditions of ultra-high performance liquid chromatography include: mobile phase A is formic acid aqueous solution, and mobile phase B is acetonitrile.

[0053] In a specific example, the conditions of ultra-high performance liquid chromatography include: gradient elution; the gradient elution method is: 0min~10min, the volume percentage of mobile phase B is maintained at 3%; 10min~50min, the volume percentage of mobile phase B changes from 3% to 15%; 50min~60min, the volume percentage of mobile phase B changes from 15% to 25%; 60min~80min, the volume percentage of mobile phase B changes from 25% to 60%; 80min~90min, the volume percentage of mobile phase B changes from 60% to 100%.

[0054] In a specific example, the conditions of ultra-high performance liquid chromatography include using CAD detection or multi-wavelength ultraviolet detection. Preferably, the conditions of ultra-high performance liquid chromatography include using multi-wavelength ultraviolet detection.

[0055] In a specific example, the wavelength of the multi-wavelength ultraviolet detection is 254nm to 281nm. Preferably, the wavelength of the multi-wavelength ultraviolet detection is 254nm. The spectrum peak information obtained at a wavelength of 254nm is relatively large and the signal response intensity is high.

[0056] In a specific example, the conditions of ultra-high performance liquid chromatography include: a flow rate of 0.1 mL / min to 0.6 mL / min; a column temperature of 35° C. to 45° C.; and a chromatographic column of octadecylsilane bonded silica gel column. It will be appreciated that in the present invention, flow rate includes but is not limited to 0.1 mL / min, 0.12 mL / min, 0.14 mL / min, 0.16 mL / min, 0.18 mL / min, 0.20 mL / min, 0.22 mL / min, 0.24 mL / min, 0.26 mL / min, 0.28 mL / min, 0.30 mL / min, 0.32 mL / min, 0.34 mL / min, 0.36 mL / min, 0.38 mL / min, 0.40 mL / min, 0.42 mL / min, 0.44 mL / min, 0.46 mL / min, 0.48 mL / min, 0.50 mL / min, 0.52 mL / min, 0.54 mL / min, 0.56 mL / min, 0.58 mL / min, and 0.60 mL / min.

[0057] It can be understood that in the present invention, the column temperature includes but is not limited to 35° C., 36° C., 37° C., 38° C., 39° C., 40° C., 41° C., 42° C., 43° C., 44° C., and 45° C. Preferably, the column temperature is 40° C.

[0058] In a specific example, the injection volume is 2 μL.

[0059] In a specific example, the dimensions of the octadecylsilane bonded silica gel column include: a particle size of 1.5 μm to 3.5 μm, a column length of 50 mm to 180 mm, and an inner diameter of 1.5 mm to 2.5 mm. Preferably, the dimensions of the octadecylsilane bonded silica gel column include: a particle size of 1.9 μm, a column length of 150 mm, and an inner diameter of 2.1 mm. More specifically, the octadecylsilane bonded silica gel column is a Hypersil gold C18 column. The selectivity obtained by selecting this column is stronger, and the separation and peak shape are better.

[0060] In a specific example, the volume fraction of formic acid in the formic acid aqueous solution is 0.1% to 0.4%. It can be understood that in the present invention, the volume fraction of formic acid in the formic acid aqueous solution includes but is not limited to 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, and 0.4%. Preferably, the volume fraction of formic acid is 0.4%.

[0061] In a specific example, preparing a mixed reference solution comprises the following steps:

[0062] The standard stock solution was prepared by mixing the reference substances of cimicifuga glycosides, cimicifuga, chlorogenic acid, magnolidin, DL-menthol, glycyrrhizic acid, glycyrrhetinic acid, ammonium glycyrrhizinate, liquiritin, isoliquiritigenin, liquiritigenin, licorice chalcone B, isoliquiritigenin, spiny licorice chalcone, licorice chalcone A, glabridin, patchouli alcohol, geraniol, epigoitrin, psoralen, rutin, quercetin, isoquercetin, luteolin, acacia glycosides, luteolin, magnolin, imperatorin, isoimperatorin and acacetin with methanol, and the solution was kept in a dark place and refrigerated. The standard stock solution was diluted before use.

[0063] More specifically, the above-mentioned reference substances were added with chromatographic grade methanol to prepare 1 mg / mL standard stock solutions, which were stored in a 4°C refrigerator away from light for future use. When used, different mixed reference substance solutions were prepared as needed.

[0064] In a specific example, preparing the test solution includes the following steps:

[0065] The magnolia rhinitis preparation is mixed with methanol having a mass fraction of 10% to 100%, ultrasonically extracted, then filtered, the filtrate is centrifuged, filtered again, and the filtrate is taken. It can be understood that the mass fraction of methanol includes but is not limited to 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 100%. Preferably, the magnolia rhinitis preparation is mixed with methanol having a mass fraction of 70%.

[0066] In a specific example, the conditions for ultrasonic extraction include: power of 120W to 145W, frequency of 35kHz to 45kHz; time of 10min to 90min; temperature of 20°C to 35°C.

[0067] In a specific example, the centrifugal conditions include: a rotation speed of 10000 rpm to 18000 rpm; a time of 5 min to 15 min; and a temperature of 4° C. to 25° C.

[0068] The present invention also provides a method for constructing a component-based identification of a Xinyi rhinitis preparation, comprising the following steps:

[0069] Take the Xinyi rhinitis preparation, mix it with 10% to 100% methanol by mass, extract it by ultrasonic, then filter it, centrifuge the filtrate, filter it again, take the filtrate, and prepare the test solution;

[0070] The test solution was subjected to ultra-high performance liquid chromatography coupled with mass spectrometry;

[0071] The conditions used in the ultra-high performance liquid chromatography are consistent with those used in the above ultra-high performance liquid chromatography.

[0072] In a specific example, the mass spectrometry conditions include: the ionization mode is electrospray ionization; the spray voltage is 3.5 kV to 5.0 kV; the ion transfer tube temperature is 320° C. to 400° C.; the maximum ion injection time of the first-stage full scan is 250 ms to 350 ms; the maximum ion injection time of the multi-stage scan is 100 ms to 200 ms;

[0073] The scanning mode is positive and negative ion scanning; the scanning range is 100m / z~1500m / z; the scanning resolution is 20000~40000; the corresponding strongest and second strongest ions in the full scan are subjected to dipole data-dependent scanning; the fragmentation mode is collision-induced fragmentation, and the collision energy is 30%~40%.

[0074] More specifically, the mass spectrometry conditions include: the ionization mode is electrospray ionization; the spray voltage is 4.5 kV; the ion transfer tube temperature is 380°C; the maximum ion injection time of the first-stage full scan is 300 ms; the maximum ion injection time of the multi-stage scan is 150 ms; the scanning mode is positive and negative ion scanning; the scanning range is 100 m / z to 1500 m / z; the scanning resolution is 30000; a dipole data-dependent scan is performed on the corresponding strongest and second strongest ions in the full scan; the fragmentation mode is collision-induced fragmentation, and the collision energy is 35%.

[0075] The present invention also provides a method for detecting a magnolia rhinitis preparation, comprising the following steps:

[0076] Take the Xinyi rhinitis preparation, mix it with 10% to 100% methanol by mass, extract it by ultrasonic, then filter it, centrifuge the filtrate, filter it again, take the filtrate, and prepare the test solution;

[0077] The solution to be tested is subjected to ultra-high performance liquid chromatography;

[0078] The conditions used in the ultra-high performance liquid chromatography are consistent with those used in the above ultra-high performance liquid chromatography.

[0079] The fingerprint construction method of the Xinyi rhinitis preparation of the present invention is further described in detail below in conjunction with specific examples. The raw materials used in the following examples, unless otherwise specified, are all commercially available products.

[0080] Example 1

[0081] This embodiment provides a method for constructing a fingerprint spectrum of a Xinyi rhinitis preparation, which is as follows:

[0082] 1. Instruments and test drugs

[0083] Instruments: Ultimate 3000 rapid separation liquid chromatography system (Dionex, USA), including: HPG-3400RS binary high pressure gradient pump, WPS-3000TRS autosampler, TCC-3000RS column oven, RS Variable variable wavelength UV detector, Corona Veo RS charged aerosol detector (CAD) and Chameleon chromatography management software (SR7.2); Milli-Q ultrapure water treatment system (Millipore, USA); high-speed cryogenic centrifuge (ThermoFisher, USA); LTQ-Orbitrap XL combined high-resolution mass spectrometer.

[0084] Reagents: Acetonitrile, methanol and formic acid were all chromatographic grade reagents, and ultrapure water (18.2 Mohm.cm) was obtained from a Milli-Q ultrapure water system.

[0085] Standard substances: cimicifugin glycosides, cimicifugin, chlorogenic acid, magnolidin, DL-menthol, glycyrrhizic acid, glycyrrhetinic acid, ammonium glycyrrhizinate, liquiritin, isoliquiritigenin, liquiritigenin, licorice chalcone B, isoliquiritigenin, licorice chalcone, licorice chalcone A, glabridin, patchouli alcohol, geraniol, epigoitrin, psoralen, rutin, quercetin, isoquercetin, luteolin, acacia glycosides, luteolin, magnolin, imperatorin, isoimperatorin, and acacetin were all purchased from Chengdu Munster Biotechnology Co., Ltd. with a purity of ≥95%. All standard substances were confirmed by UV absorption spectroscopy, high-resolution mass spectrometry, and multi-stage fragmentation data before use.

[0086] Experimental samples: All batches of Xinyi Biyan Pills finished product samples in the experiment were provided by Guangzhou Zhongyi Pharmaceutical Co., Ltd., see Table 1 for details.

[0087] Table 1 Xinyi Biyan Pills Samples

[0088]

[0089] 2. Methods

[0090] 2.1 Chromatographic conditions

[0091] The chromatographic column was ThermoFisher Hypersil gold C18 (150mm×2.1mm, 1.9μm), and the guard column was ThermoFisher Hypersil gold C18 (2.1mm ID, 0.2μm). The mobile phase A was 0.1% formic acid water, and B was acetonitrile. The gradient elution was: -10~0min, 3% B; 0~10min, 3% B; 10~50min, 3%~15% B; 50~60min, 15%~25% B; 60~80min, 25%~60% B; 80~90min, 60%~100% B. Flow rate: 0.4mL / min; column temperature: 40℃; injection volume: 2μL. UV detector (VWD) detection conditions, detection wavelength: 254nm; sampling frequency: 5Hz.

[0092] Ionization mode: electrospray ionization; spray voltage: 4.5 kV; ion transfer tube temperature: 380 °C; maximum ion injection time: 300 ms for first-stage full scan and 150 ms for multi-stage scan.

[0093] Scanning mode: positive and negative ion scanning; scanning range: m / z 100-1500; scanning resolution: 30,000; secondary data-dependent scanning is performed on the first two strongest ions with the strongest response in the full scan; fragmentation mode: collision-induced fragmentation (CID), energy 35%.

[0094] 2.2 Preparation of test solution

[0095] Accurately weigh about 1 g of Xinyi Biyan Pill powder, accurately weigh it, place it in a stoppered conical flask, accurately add 10 mL of methanol, seal it, weigh the mass, and ultrasonically treat it (BRANSON 5510; power / frequency, 135 W / 42 kHz) for 30 min. Let it cool, weigh it, make up the weight loss with 70% methanol, shake it well, let it stand, take the supernatant and high-speed centrifuge it at 14000 rpm for 10 min, take the supernatant and place it in a liquid chromatography injection bottle to obtain the product.

[0096] 2.3 Preparation of reference solution

[0097] Accurately weigh appropriate amounts of 30 standard substances, dissolve them in chromatographic methanol and make up to 2 mL as standard stock solutions, and store them in a refrigerator at 4°C for later use.

[0098] 2.4 Data Processing

[0099] All the spectra in the experiment were processed and exported by Chameleon Chromatography Management Software (SR7.2); the exported sample spectra were analyzed by fingerprint analysis using the "Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System V2.0" (Chinese Pharmacopoeia Committee) to calculate the sample similarity.

[0100] 3. Results and Discussion

[0101] 3.1 Methodological investigation

[0102] 3.1.1 Precision

[0103] The test solution was prepared according to the sample preparation method, and the sample was injected 6 times continuously for UPLC analysis. The results showed that the RSD values ​​of the relative peak area and relative retention time of each common peak were less than 4.8% and 0.6%, respectively, indicating that the instrument had good precision and met the requirements of the fingerprint spectrum.

[0104] 3.1.2 Stability

[0105] The test solution was prepared according to the sample preparation method, and UPLC analysis was performed at 0, 3, 6, 9, 12 and 24 h. The results showed that the RSD values ​​of the relative peak area and relative retention time of each common peak were less than 5.1% and 0.6%, respectively, indicating that the sample solution had good stability within 24 h.

[0106] 3.1.3 Repeatability

[0107] Five samples of Xinyi Biyan Pills from the same batch were taken and the test solutions were prepared according to the sample preparation method. UPLC analysis was performed. The results showed that the RSD values ​​of the relative peak area and relative retention time of each common peak were less than 4.8% and 0.7%, respectively, indicating that the method had good repeatability.

[0108] 3.2 Establishment of standard fingerprint

[0109] 3.2.1 Establishment of fingerprint

[0110] Take 12 batches of Xinyi Biyan Pills samples, prepare sample test solutions according to the method in "2.2", perform UPLC-UV analysis according to the chromatographic conditions in "2.1", and record the 90-min chromatogram.

[0111] 3.2.2 Selection of reference peak

[0112] In the spectrum, a chromatographic peak with a large peak area, moderate elution time and stability was selected as the reference peak. The chromatographic peak with a retention time of 37.58 min met this condition. After comparison with the standard and mass spectrometry, it was confirmed to be the chromatographic peak of cimicifuga glycoside. Therefore, the chromatographic peak of cimicifuga glycoside was selected as the reference peak. Fig.10 shown.

[0113] 3.2.3 Reference spectrum and common peak calibration

[0114] The UPLC fingerprints of 12 batches of samples were imported into the "Chinese Medicine Chromatographic Fingerprint Recognition Evaluation System", and the S4 sample spectrum was used as the reference spectrum. The median method was used to automatically match the spectrum peaks. Figure 1 As shown, a control fingerprint is generated and a common pattern is established, such as Figure 2 As shown. Chromatographic peaks with good stability, strong absorption and obvious characteristics were selected as common peaks, and 32 common peaks were determined based on the measurement results of 12 batches of samples. According to the selected cimicifuga glycoside as the reference peak (peak 18), its retention time and peak area were set to 1.0, and the relative retention time and relative peak area of ​​each common peak were calculated and listed in Table 2 and Table 3 respectively.

[0115] Table 2. Relative retention time of common peaks in fingerprints of 12 batches of Xinyi Biyan Pills

[0116]

[0117]

[0118] Table 3. Relative retention peak areas of common peaks in fingerprints of 12 batches of Xinyi Biyan Pills

[0119]

[0120]

[0121] 3.2.4 Similarity evaluation

[0122] The HPLC fingerprints of 12 batches of samples were imported into the "Chinese Medicine Chromatographic Fingerprint Similarity Evaluation System" to generate the control fingerprint of Xinyi Biyan Pills. In the analytical test mode, the similarity of the fingerprints of the 12 batches of samples was calculated. The results showed that the similarity between the 12 batches of samples and the control fingerprint was greater than >0.961, as shown in Table 4.

[0123] Table 4. Fingerprint similarity

[0124]

[0125] 3.2.5 Analysis of common peak attribution

[0126] The same chromatographic conditions were used to determine the spectra of each standard and the whole formula sample. After comparison with the chromatogram of the reference solution and confirmation by mass spectrometry, it was shown that among the characteristic peaks of the fingerprint spectrum, peak No. 19 was cimicifuga glycoside, peak No. 19 was rutin, peak No. 21 was luteolin, peak No. 22 was cimicifuga, peak No. 29 was luteolin, and peak No. 32 was glycyrrhizic acid.

[0127] Example 2

[0128] This example provides a condition investigation of the fingerprint spectrum construction method of the Xinyi rhinitis preparation, which is as follows:

[0129] 1. Extraction process

[0130] 1.1 Extraction solvent

[0131] The extraction solvent system of Xinyi Biyan Pill fingerprint sample solution was investigated, and the ultrasonic extraction efficiency of 4 solvent systems including 10%, 40%, 70% and 100% methanol was compared. Figure 3 As shown in the figure, with the increase of methanol concentration in the extraction solvent, the number of detected chromatographic peaks gradually increased, especially the peaks of components with weaker polarity. At the same time, the intensity of the chromatographic peaks also gradually increased, indicating that the extraction efficiency was improved. However, when 100% methanol was used as the extraction solvent, the intensity of the main chromatographic peaks was significantly weakened. Therefore, 70% methanol with the highest extraction efficiency was selected as the extraction solvent for the fingerprint sample of Xinyi Biyan Pills.

[0132] 1.2 Extraction time

[0133] After selecting methanol as the extraction solvent, the ultrasonic extraction time of the Xinyi Biyan Pill fingerprint sample solution was investigated, including 10min, 20min, 30min, 60min, and 90min. The results are as follows Figure 4 As shown in the figure, with the increase of extraction time, the response intensity of each chromatographic peak gradually increases. When the extraction time is 30 min, the chromatographic peak intensity reaches the highest. When the extraction time is 60 min and 90 min, the chromatographic peak intensity does not increase significantly, but decreases slightly. Therefore, based on the principle of high extraction efficiency and time saving, 30 min is preferred as the ultrasonic extraction time for the fingerprint sample of Xinyi Biyan Pills.

[0134] 2. Chromatographic conditions

[0135] UPLC is used to separate and detect the sample solution, and the separation conditions are optimized, including detector type, chromatographic column type, chromatographic column temperature, mobile phase composition, mobile phase additives, etc., so that the analyzed samples can obtain as many baseline-separated chromatographic peaks as possible in the shortest time.

[0136] 2.1 Detector

[0137] Since Xinyi Biyan Pills is composed of 13 Chinese herbs, the number, properties and types of its chemical components are very large, so the fingerprint established in this experiment should obtain as much information as possible on the chemical components. Therefore, this experiment first selected the VWD ultraviolet detector (with multi-wavelength detection) and the CAD detector for comparison. The results are shown in Figure 2. Figure 5 As shown in the figure, under the CAD detector, the chromatogram obtained by the sample has low chromatographic peak intensity and poor sensitivity; while under the VWD ultraviolet detector, the sample component signal response is strong and the sensitivity is high. Therefore, this experiment selects the VWD ultraviolet detector for the Xinyi Biyan Pill fingerprint study. In addition, under 281nm ultraviolet detection, the signal response intensity of the polar component in the spectrum is high, while the signal intensity of the medium polarity and weak polarity components is low and the number of visible peaks is small; after changing the detection wavelength to 254nm, the number of chromatographic peaks of the medium polarity and weak polarity components in the corresponding chromatogram increases significantly and the signal response intensity is high. Therefore, this experiment selects the ultraviolet detection wavelength of 254nm.

[0138] 2.2 Chromatographic column

[0139] In this experiment, three different types of chromatographic columns were investigated under the same chromatographic conditions, including ThermoFisher Hypersil gold C18 (150mm×2.1mm, 1.9μm), Waters BEH C18 (100mm×2.1mm, 1.7μm) and ThermoFisher Hypersil gold C8 (150mm×2.1mm, 3μm). The results showed that the Hypersil gold C18 column had stronger selectivity, better separation and peak shape, so the Hypersil gold C18 column was selected for subsequent fingerprint study.

[0140] 2.3 Mobile phase

[0141] In the experiment, methanol-water and acetonitrile-water were first investigated as mobile phases. The results showed that when acetonitrile-water was used as the mobile phase for gradient elution, there were more chromatographic peaks, better peak shape, and faster elution speed. Therefore, the acetonitrile-water system was selected for research. Figure 6 At the same time, in order to further improve the peak shape and enhance the chromatographic peak separation, the experiment investigated different concentrations of formic acid as a mobile phase additive, including acetonitrile-0.1% formic acid water, acetonitrile-0.2% formic acid water and acetonitrile-0.4% formic acid water. Figure 7It can be seen that under different additive concentration conditions, there is no obvious difference in the chromatograms, but in the acetonitrile-0.1% formic acid water mobile phase system, the mixed single chromatographic peak with a retention time of 42min is separated into two baseline-separated chromatographic peaks, which improves the resolution; at the same time, considering the tolerance of the chromatographic column to the acidic mobile phase and the repeatability of the experiment, this experiment uses acetonitrile-0.1% formic acid water as the mobile phase for gradient elution analysis.

[0142] 2.4 Column temperature

[0143] The temperature of the chromatographic column has a great influence on the separation effect of structural analogs. This experiment investigated the effects of different chromatographic column temperatures (35℃, 40℃, 45℃) on sample separation. Figure 8 It can be seen that when the column temperature is 35℃, 40℃, and 45℃, the separation effects of each chromatographic peak are similar, and good peak shapes can be obtained. In view of the life of the column and the repeatability of the experiment, the column temperature was selected as 40℃ in this experiment.

[0144] 2.5 Gradient Program

[0145] Xinyi Biyan Pills are composed of 13 Chinese medicinal materials, with a large number of chemical components. Fingerprinting requires the separation and characterization of chemical components contained in the sample as much as possible. Therefore, this study uses 1.9μm particle size ultra-high performance liquid chromatography columns based on UPLC-UV technology to perform chromatographic efficient and rapid separation and analysis of samples. At the same time, due to the different properties of the chemical components contained, we optimized the gradient elution program in order to separate the maximum number of chromatographic peaks in the shortest time. After optimization, the sample was analyzed within 90 minutes. Fig. 9 As shown, the preferred gradient program is as follows:

[0146] The mobile phase A was 0.1% formic acid water, and B was acetonitrile. The gradient elution was: -10 to 0 min, 3% B; 0 to 10 min, 3% B; 10 to 50 min, 3% to 15% B; 50 to 60 min, 15% to 25% B; 60 to 80 min, 25% to 60% B; 80 to 90 min, 60% to 100% B.

[0147] Example 3

[0148] This embodiment provides a mass spectrometry identification method for the chemical components of a Xinyi rhinitis preparation, which is as follows:

[0149] The established fingerprint chromatography method was used in series with LTQ-Orbitrap combined high-resolution mass spectrometry to detect the compound samples in positive and negative ion modes, such as Fig.11 As shown in Table 5, a total of 141 compounds were identified after comparing the obtained accurate mass and multi-level fragment information with relevant literature and compound standard substances.

[0150] Table 5 Mass spectrometry identification results of Xinyi Biyan Pill compounds

[0151]

[0152]

[0153]

[0154]

[0155]

[0156]

[0157]

[0158] *Confirmed by reference standards

[0159] The technical features of the above-described embodiments may be arbitrarily combined. To make the description concise, not all possible combinations of the technical features in the above-described embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0160] The above-described embodiments only express several implementation methods of the present invention, which are convenient for understanding the technical solutions of the present invention in detail, but they cannot be understood as limiting the scope of protection of the invention patent. It should be pointed out that for ordinary technicians in this field, several modifications and improvements can be made without departing from the concept of the present invention, which all belong to the protection scope of the present invention. It should be understood that the technical solutions obtained by those skilled in the art through logical analysis, reasoning or limited experiments on the basis of the technical solutions provided by the present invention are all within the protection scope of the claims attached to the present invention. Therefore, the protection scope of the patent of the present invention shall be based on the contents of the attached claims, and the description and drawings can be used to interpret the contents of the claims.

Claims

1. A method for constructing a fingerprint spectrum of a magnolia rhinitis preparation, characterized in that: The steps include: Mix the reference substances of cimicifugin glycoside, cimicifugin, chlorogenic acid, magnolidin, DL-menthol, glycyrrhizic acid, glycyrrhetinic acid, ammonium glycyrrhizinate, liquiritin, isoliquiritigenin, liquiritigenin, licorice chalcone B, isoliquiritigenin, licorice chalcone A, glabridin, patchouli alcohol, geraniol, epigoitrin, psoralen, rutin, quercetin, isoquercetin, luteolin, acacia glycoside, luteolin, magnolin, imperatorin, isoimperatorin, and acacetin with methanol to prepare a mixed reference substance solution; Take the Xinyi rhinitis preparation and prepare the test solution; Performing ultra-high performance liquid chromatography on the mixed reference solution and the test solution respectively; The conditions of the ultra-high performance liquid chromatography include: mobile phase A is a formic acid aqueous solution, and mobile phase B is acetonitrile; the volume fraction of formic acid in the formic acid aqueous solution is 0.1% to 0.4%; Gradient elution is adopted; the gradient elution mode is as follows: from 0min to 10min, the volume percentage of mobile phase B is maintained at 3%; from 10min to 50min, the volume percentage of mobile phase B changes from 3% to 15%; from 50min to 60min, the volume percentage of mobile phase B changes from 15% to 25%; from 60min to 80min, the volume percentage of mobile phase B changes from 25% to 60%; from 80min to 90min, the volume percentage of mobile phase B changes from 60% to 100%; Electrospray detection or multi-wavelength ultraviolet detection is adopted; the wavelength of the multi-wavelength ultraviolet detection is 254nm-281nm.

2. The fingerprint spectrum construction method of the Xinyi rhinitis preparation according to claim 1, characterized in that: The conditions of the ultra-high performance liquid chromatography include: a flow rate of 0.1 mL / min to 0.6 mL / min; a column temperature of 35° C. to 45° C.; and a chromatographic column of octadecylsilane bonded silica gel column.

3. The fingerprint spectrum construction method of the Xinyi rhinitis preparation according to claim 2, characterized in that: The dimensions of the octadecylsilane bonded silica gel column include: a particle size of 1.5 μm to 3.5 μm, a column length of 50 mm to 180 mm, and an inner diameter of 1.5 mm to 2.5 mm.

4. The method for constructing the fingerprint spectrum of the Xinyi rhinitis preparation according to any one of claims 1 to 3, characterized in that: The preparation of the mixed reference solution comprises the following steps: The standard stock solution was prepared by mixing the reference substances of cimicifuga glycosides, cimicifuga, chlorogenic acid, magnolidin, DL-menthol, glycyrrhizic acid, glycyrrhetinic acid, ammonium glycyrrhizinate, liquiritin, isoliquiritigenin, liquiritigenin, licorice chalcone B, isoliquiritigenin, spiny licorice chalcone, licorice chalcone A, glabridin, patchouli alcohol, geraniol, epigoitrin, psoralen, rutin, quercetin, isoquercetin, luteolin, acacia glycosides, luteolin, magnolin, imperatorin, isoimperatorin and acacetin with methanol, and the solution was stored in a dark place and refrigerated. The standard stock solution was diluted before use.

5. The method for constructing the fingerprint spectrum of the Xinyi rhinitis preparation according to any one of claims 1 to 3, characterized in that: The preparation of the test solution includes the following steps: The magnolia nasitis preparation is mixed with methanol with a mass fraction of 10% to 100%, ultrasonically extracted, and then filtered. The filtrate is centrifuged and filtered again to obtain the filtrate.

6. The method for constructing the fingerprint spectrum of the Xinyi rhinitis preparation according to claim 5, characterized in that: The conditions for ultrasonic extraction include: power of 120W to 145W, frequency of 35kHz to 45kHz, time of 10min to 90min, and temperature of 20℃ to 35℃.

7. A method for constructing a component-based identification of a magnolia rhinitis preparation, characterized in that: The steps include: Take the Xinyi rhinitis preparation, mix it with 10% to 100% methanol by mass, extract it by ultrasonic, then filter it, centrifuge the filtrate, filter it again, take the filtrate, and prepare the test solution; The test solution is subjected to ultra-high performance liquid chromatography-mass spectrometry; The conditions used in the ultra-high performance liquid chromatography are consistent with the conditions used in the ultra-high performance liquid chromatography described in any one of claims 1 to 3.

8. The method for constructing the component-based identification of the Xinyi rhinitis preparation according to claim 7, characterized in that: The mass spectrometry conditions include: the ionization mode is electrospray ionization; the spray voltage is 3.5 kV to 5.0 kV; the ion transfer tube temperature is 320°C to 400°C; the maximum ion injection time of the first-stage full scan is 250 ms to 350 ms; the maximum ion injection time of the multi-stage scan is 100 ms to 200 ms; The scanning mode is positive and negative ion scanning; the scanning range is 100m / z~1500m / z; the scanning resolution is 20000~40000; the corresponding strongest and second strongest ions in the full scan are subjected to dipole data-dependent scanning; the fragmentation mode is collision-induced fragmentation, and the collision energy is 30%~40%.

9. A method for detecting a magnolia rhinitis preparation, characterized in that: The steps include: Take the Xinyi rhinitis preparation, mix it with 10% to 100% methanol by mass, extract it by ultrasonic, then filter it, centrifuge the filtrate, filter it again, take the filtrate, and prepare the test solution; The solution to be tested is subjected to ultra-high performance liquid chromatography; The conditions used in the ultra-high performance liquid chromatography are consistent with the conditions used in the ultra-high performance liquid chromatography described in any one of claims 1 to 3.